Literature DB >> 1281470

Molecular basis for the species selectivity of the neurokinin-1 receptor antagonists CP-96,345 and RP67580.

T M Fong1, H Yu, C D Strader.   

Abstract

Two non-peptide substance P antagonists exhibit opposite rank orders of potency for the human and rat neurokinin-1 receptors. CP-96,345 shows selectivity for the human receptor, whereas RP67580 shows selectivity for the rat receptor. Amino acid sequence comparison of the two receptors reveals 22 divergent residues. To elucidate the molecular basis for the species selectivity of these antagonists, divergent residues in the human neurokinin-1 receptor were substituted by the rat homologs. Analysis of mutant receptors revealed that substitution of 2 residues (V116L and I290S) in the transmembrane domain of the human neurokinin-1 receptor is both necessary and sufficient to reproduce the antagonist binding affinities of the rat receptor. The nature of these substitutions and the magnitude of the changes in binding affinity suggest that residues 116 and 290 do not interact directly with the antagonist molecules. The present results support a model in which phylogenetically conserved residues interact directly with the antagonists, while phylogenetically divergent residues affect the local helical packing of the receptor. Such a change in local structure would lead to increased binding affinity for one class of antagonists and decreased affinity for another.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1281470

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition.

Authors:  Q Jiang; A M Van Rhee; J Kim; S Yehle; J Wess; K A Jacobson
Journal:  Mol Pharmacol       Date:  1996-09       Impact factor: 4.436

2.  Molecular Architecture of G Protein-Coupled Receptors.

Authors:  A Michiel van Rhee; Kenneth A Jacobson
Journal:  Drug Dev Res       Date:  1996-01-01       Impact factor: 4.360

Review 3.  Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides.

Authors:  B L Kieffer
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

Review 4.  Modes of peptide binding in G protein-coupled receptors.

Authors:  M Berthold; T Bartfai
Journal:  Neurochem Res       Date:  1997-08       Impact factor: 3.996

5.  The molecular basis for high affinity of a universal ligand for human bombesin receptor (BnR) family members.

Authors:  Hirotsugu Uehara; Simon J Hocart; Nieves González; Samuel A Mantey; Tomoo Nakagawa; Tatsuro Katsuno; David H Coy; Robert T Jensen
Journal:  Biochem Pharmacol       Date:  2012-07-22       Impact factor: 5.858

6.  Generation of mice expressing the human glucagon receptor with a direct replacement vector.

Authors:  L L Shiao; M A Cascieri; M Trumbauer; H Chen; K A Sullivan
Journal:  Transgenic Res       Date:  1999-08       Impact factor: 2.788

7.  Two nonpeptide tachykinin antagonists act through epitopes on corresponding segments of the NK1 and NK2 receptors.

Authors:  U Gether; Y Yokota; X Emonds-Alt; J C Brelière; J A Lowe; R M Snider; S Nakanishi; T W Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

8.  Effect of the tachykinin receptor antagonists, SR 140333, FK 888, and SR 142801, on capsaicin-induced mouse ear oedema.

Authors:  H Inoue; N Nagata; Y Koshihara
Journal:  Inflamm Res       Date:  1996-06       Impact factor: 4.575

9.  Antinociceptive activity of NK1 receptor antagonists: non-specific effects of racemic RP67580.

Authors:  N M Rupniak; S Boyce; A R Williams; G Cook; J Longmore; G R Seabrook; M Caeser; S D Iversen; R G Hill
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

10.  Molecular basis for the selectivity of the mammalian bombesin peptide, neuromedin B, for its receptor.

Authors:  Nieves González; Tomoo Nakagawa; Samuel A Mantey; Veronica Sancho; Hirotsugu Uehara; Tatsuro Katsuno; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2009-07-23       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.